Get started
Author

Andrew D. Fesnak

Observed names: A. Fesnak, A.D. Fesnak, Andrew Fesnak, Fesnak, Andrew D.
ORCID: 0000-0002-2705-803X
Observed ORCID: 0000-0002-2705-803X
OpenAlex ID: A5073009158
CRISPR-engineered T cells in patients with refractory cancer
2020 · Edward A. Stadtmauer, Joseph A. Fraietta, et al. · Science · 1,472
Engineered T cells: the promise and challenges of cancer immunotherapy
2016 · Andrew D. Fesnak, Carl H. June, et al. · Nature reviews. Cancer · 1,070
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
2021 · Mohamed Abou-el-Enein, Magdi Elsallab, et al. · Blood Cancer Discovery · 321
PDF
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
2021 · Regina M. Myers, Yimei Li, et al. · Journal of Clinical Oncology · 192
CAR-T Cell Therapies From the Transfusion Medicine Perspective
2016 · Andrew Fesnak, ChieYu Lin, et al. · Transfusion Medicine Reviews · 82
NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT
2015 · Mobin A. Karimi, Jerrod L. Bryson, et al. · Blood · 50
The Challenge of Variability in Chimeric Antigen Receptor T Cell Manufacturing
2019 · Andrew D. Fesnak · Regenerative Engineering and Translational Medicine · 45
A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies
2019 · Kan Wang, Yi Liu, et al. · Cytotherapy · 29
In their own words: Patients and families define high-quality palliative care in the intensive care unit
2011 · A.D. Fesnak, V.K. Rajput · Yearbook of Critical Care Medicine · 21
Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
2019 · Alfred L. Garfall, Adam D. Cohen, et al. · Blood · 20
Clinical Development and Manufacture of Chimeric Antigen Receptor T cells and the Role of Leukapheresis
2017 · Andrew Fesnak, Una O’Doherty · European Oncology & Haematology · 17
PDF
CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL
2021 · Noelle V Frey, Saar Gill, et al. · Blood · 15
First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma
2019 · Edward A. Stadtmauer, Adam D. Cohen, et al. · Blood · 13
Place of Academic GMP Facilities in Modern Cell Therapy
2019 · Alexey Bersenev, Andrew Fesnak · Methods in molecular biology · 11
Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy
2017 · Andrew D. Fesnak, Patrick J. Hanley, et al. · Current Hematologic Malignancy Reports · 11
Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL)
2017 · M.M. Davis, A. Fesnak, et al. · Cytotherapy · 11
How do I: Evaluate the safety and legitimacy of unproven cellular therapies?
2022 · Indira Guleria, Maria de Los Angeles Muñiz, et al. · Transfusion · 9
A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy
2023 · Kan Wang, Chin-Yuan Tseng, et al. · Cytotherapy · 6
Violations of the 12/23 rule at the mouse immunoglobulin kappa locus, including Vκ-Vκ rearrangement
2009 · Jeffrey M. Vinocur, Andrew D. Fesnak, et al. · Molecular Immunology · 5
Limiting variability to achieve reproducibility in cell manufacturing
2020 · Anne Lamontagne, Andrew Fesnak · Cell and Gene Therapy Insights · 4
Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells)
2020 · J. Xu, M. Gohil, et al. · Cytotherapy · 4
Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis
2023 · Ethan A. Mack, Meaghan C. Dougher, et al. · Blood · 3
PDF
Clinical development of natural killer cells expressing chimeric antigen receptors
2021 · Ryan J. Golden, Andrew D. Fesnak · Transfusion and Apheresis Science · 3
PDF
Robust automated cell counter and viability measurement for engineered T cell product release
2018 · Y. Ohayon, C.M. Corl, et al. · Cytotherapy · 3
Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia
2025 · Lucy Cain, Yimei Li, et al. · Blood · 2
Works count: 53
Citation count: 3,426
H-index: 13
I10-index: 16
Year
Topic
Type